ArticleBMC rheumatology2026
Weight loss ameliorates symptoms of osteoarthritis and is correlated with alterations in soluble bone and cartilage markers: an analysis of patient-reported outcomes and biomarkers.
Article in BMC rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Subjects With Knee Osteoarthritis
A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Subjects With Knee Osteoarthritis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDrug development for osteoarthritis (OA) has faced significant challenges, mainly due to the lack of alignment between joint structure observations and patient-reported outcomes (PROs), such as pain. Weight loss has been linked to positive effects on symptomatic outcomes. Blood-based biomarkers indicating collagen and extracellular matrix turnover can be used to measure injury severity in specific tissues, offering a more precise assessment of disease progression. This study aimed to explore the relationship between obesity and PROs and its impact on serum and urinary biomarkers of bone (CTX-I and osteocalcin), synovial (type III collagen degradation and C3M), and cartilage (type II collagen degradation, CTX-II, and C2M) turnover.
methodsThis post hoc exploratory analysis examined data from 806 patients with persistent knee OA pain who participated in two clinical trial of oral salmon calcitonin (NCT00704847 [2008-06] and NCT00486434 [2007-06]. Participants were categorized by baseline BMI (lean, overweight, and obese) and two-year weight change (gain/loss ≥5%). Biomarkers were measured at baseline and at the 2-year follow-up.
resultsThe cohort primarily consisted of white women, with a median age of 64 years and a median BMI of 29 kg/m
conclusionObesity exacerbates OA symptoms. While weight loss improves symptoms and reduces synovial inflammation, measured by biomarkers, it may also heighten the risk of excessive bone and cartilage loss, when using specific collagen degradation biomarkers. This study is a post-hoc analysis of data from the CSMC trials with clinicaltrial.gov numbers NCT00704847 (2008-06-24) and NCT00486434 (2007-06-14).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.